Inhibition of NF-κB activity, with a specific p65 antisense oligonucleotide, is effective in preventing experimental models of IBD, and it markedly downregulates proinflammatory cytokine production in intestinal macrophages in IBD patients [5, 6]. Here, NFKB1 is linked to inflammatory bowel disease.